Lambert-Eaton Myasthenic Syndrome (LEMS)
LEMS is a rare autoimmune disorder of the neuromuscular junction characterized by proximal muscle weakness (especially in the legs), reduced or absent reflexes, and autonomic dysfunction, caused by antibodies against presynaptic voltage-gated calcium channels (VGCCs) that impair acetylcholine release. 1
Pathophysiology
The disease mechanism is well-defined: more than 90% of LEMS patients have antibodies against P/Q-type VGCCs 1. These antibodies directly block calcium channel function and decrease calcium influx into the presynaptic nerve terminal, preventing the release of acetylcholine-containing vesicles and resulting in decreased synaptic transmission at the neuromuscular junction 1. This reduced quantal content of acetylcholine release means the post-synaptic summative endplate potential is insufficient to trigger muscle fiber contraction, manifesting as weakness 2.
Clinical Presentation
The hallmark clinical features are craniocaudally progressive proximal muscle weakness that occurs predominantly at the hip girdle, with characteristic spread from legs upward to arms and eventually oculobulbar muscles in severe cases 1, 2.
Key clinical features include:
- Proximal leg weakness as the initial and predominant symptom
- Reduced or absent deep tendon reflexes (areflexia)
- Autonomic dysfunction: dry mouth (most common), impotence, sweating disturbances, orthostatic hypotension 1, 3, 2
- Progression to respiratory muscles in severe cases 2
- Symptoms may improve with repeated muscle use (post-exercise facilitation)
Critical Association with Malignancy
LEMS has a 50-60% association with small cell lung cancer (SCLC), making it a crucial early indicator of malignancy 4, 5, 6. The prevalence of LEMS in SCLC patients is 1% to 1.6% 1. This paraneoplastic form (P-LEMS) must be distinguished from the autoimmune form (A-LEMS or NT-LEMS), which is often associated with other autoimmune diseases 7, 6.
A LEMS diagnosis should immediately trigger vigorous oncological screening and surveillance for SCLC 6, 8. Delayed diagnosis correlates with later initiation of cancer therapy 3, making early recognition critical for patient outcomes.
Diagnostic Approach
Diagnosis relies on three pillars 1, 7:
1. Clinical Characteristics
Look for the specific pattern: proximal leg weakness with autonomic symptoms and areflexia
2. Electromyography (EMG) Findings
Characteristic electrodiagnostic features include:
- Small compound muscle action potentials (CMAPs) at rest
- Significant decrement at low-frequency (2-5 Hz) repetitive nerve stimulation
- Increment at high-frequency (20-50 Hz) repetitive nerve stimulation or after brief exercise (>100% increment is typical) 2, 7
These findings reflect the presynaptic transmission defect and are key confirmatory criteria 7.
3. Serological Testing
Anti-VGCC antibodies (specifically P/Q-type) are present in approximately 90% of patients 1, 5. However, routine measurement of VGCC antibodies is NOT recommended in the absence of clinical features of LEMS 1. The antibodies should be carefully interpreted only when there is clinical suspicion with characteristic features 7.
Treatment Strategy
For Paraneoplastic LEMS (with SCLC)
Oncological treatment of the underlying tumor takes priority 6. Response to SCLC therapy favorably affects the course of LEMS 1.
Symptomatic Treatment
3,4-diaminopyridine (amifampridine) is the primary symptomatic treatment, which works by blocking potassium channels and increasing acetylcholine release at the nerve terminal 2, 5, 7, 6.
Immunotherapy
Intravenous immunoglobulin (IVIg) is a potential treatment for LEMS 1. Guidelines for using IVIg for LEMS have been proposed 1. Additional immunosuppressive options include prednisone plus azathioprine for persistent symptoms 6, or combinations of methylprednisolone and cyclophosphamide 1.
Prognosis
Life expectancy in non-tumor LEMS (NT-LEMS) is normal, though complete remission is uncommon 2. In paraneoplastic LEMS (P-LEMS), prognosis is determined by SCLC progression, though outcomes are better than in SCLC patients without LEMS 2. The cause of death in SCLC-LEMS is typically tumor progression 6.
Clinical Pitfalls
- Do not confuse with myasthenia gravis: LEMS has proximal leg predominance and areflexia, while myasthenia gravis typically presents with ocular/bulbar symptoms and normal reflexes
- Do not delay cancer screening: The association with SCLC is strong enough that any LEMS diagnosis mandates immediate and ongoing tumor surveillance
- Do not order VGCC antibodies as a screening test: Only order when clinical features suggest LEMS, as false positives can occur
- Recognize that paraneoplastic encephalomyelitis may precede tumor diagnosis 4, so comprehensive paraneoplastic antibody panels should be considered when neurologic paraneoplastic syndrome is suspected